Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Huang H"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 58
Tytuł:
A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Autorzy:
Huang H; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Zhang H; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Cao B; Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 427-433. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Sarcoma*/drug therapy
Sarcoma*/pathology
Piperidines*
Pyridines*
Pyrimidines*
Humans ; Phosphatidylinositol 3-Kinases ; Clinical Trials, Phase I as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Autorzy:
Hart L; Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.; Wake Forest University School of Medicine, North Carolina, Winston-Salem, USA.
Ogbonnaya A; Wake Forest University School of Medicine, North Carolina, Winston-Salem, USA.
Boykin K; Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.
Deyoung K; Xcenda LLC, Texas, Carrolton, USA.
Bailey R; Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.
Heritage T; Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.
Lopez-Gonzalez L; G1 Therapeutics, Inc., North Carolina, Research Triangle Park, USA.
Huang H; G1 Therapeutics, Inc., North Carolina, Research Triangle Park, USA.
Gordan L; Florida Cancer Specialists & Research Institute, Florida, Fort Myers, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 10020-10030. Date of Electronic Publication: 2023 Mar 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Small Cell Lung Carcinoma*/drug therapy
Bone Marrow Diseases*/etiology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/etiology
Antineoplastic Agents*/therapeutic use
Adult ; Humans ; Retrospective Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Engineering defected 2D Pd/H-TiO 2 nanosonosensitizers for hypoxia alleviation and enhanced sono-chemodynamic cancer nanotherapy.
Autorzy:
Qiao X; Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
Xue L; Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
Huang H; Shanghai Engineering Research Center of Organ Repair, Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, People's Republic of China.
Dai X; Shanghai Engineering Research Center of Organ Repair, Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, People's Republic of China. .
Chen Y; Shanghai Engineering Research Center of Organ Repair, Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, People's Republic of China. .
Ding H; Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China. ding_.
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2022 Apr 12; Vol. 20 (1), pp. 186. Date of Electronic Publication: 2022 Apr 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Neoplasms*/drug therapy
Ultrasonic Therapy*/methods
Cell Line, Tumor ; Humans ; Hypoxia/drug therapy ; Oxygen ; Palladium/pharmacology ; Palladium/therapeutic use ; Reactive Oxygen Species ; Titanium
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Highly Efficient Ir(III)-Coumarin Photo-Redox Catalyst for Synergetic Multi-Mode Cancer Photo-Therapy.
Autorzy:
Fan Z; School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, P. R. China.
Xie J; College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, P. R. China.
Sadhukhan T; Department of Chemistry, Indiana University, Bloomington, Indiana, 47405, USA.
Liang C; College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, P. R. China.
Huang C; School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, P. R. China.
Li W; School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, P. R. China.
Li T; School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, P. R. China.
Zhang P; College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, P. R. China.
Banerjee S; Department of Chemistry, Indian Institute of Technology (BHU), Varanasi, UP-221005, India.
Raghavachari K; Department of Chemistry, Indiana University, Bloomington, Indiana, 47405, USA.
Huang H; School of Pharmaceutical Science (Shenzhen), Sun Yat-sen University, Guangzhou, 510275, P. R. China.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2022 Jan 13; Vol. 28 (3), pp. e202103346. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Coordination Complexes*
Neoplasms*
Animals ; Cell Line, Tumor ; Coumarins ; Iridium ; Mice ; Oxidation-Reduction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein.
Autorzy:
Huang H; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Yang W; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Hu J; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Jiang Y; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Wang J; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Shi C; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Kang Y; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Wang D; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Wang C; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Yang G; College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Key Laboratory of animal production and product quality safety of Ministry of Education, Jilin Agricultural University, Changchun, China.
Pokaż więcej
Źródło:
Parasite immunology [Parasite Immunol] 2021 Jun; Vol. 43 (6), pp. e12825. Date of Electronic Publication: 2021 Feb 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Eimeria*
Neoplasms*/drug therapy
Angiogenesis Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Protozoan Proteins/*pharmacology
Animals ; B7-1 Antigen ; CD8-Positive T-Lymphocytes ; Killer Cells, Natural ; Mice ; Neoplasm Metastasis/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Progress on clinical trials of cancer drugs in China, 2020].
Autorzy:
Wu DW; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Huang HY; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Tang Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang HX; National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Wang J; National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Wang SH; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fang H; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yang XY; Hospital Office, Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing 210042, China.
Li J; National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardivascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Wang X; National Clinical Research Center for Geriatric Diseases/Clinical Trial Center, Beijing Hospital, Beijing 100730, China.
Liu LJ; Department of Clinical Trials Center, National Clinial Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
Yan Y; Department of Clinical Trials Institution, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100144, China.
Wang Q; Department of Clinical Trials Center, China-Japan Friendship Hospital, Beijing 100029, China.
Li N; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Cao C; ZhongGuanCun JiuTai Drug Clinical Practice Union, Beijing 100027, China.
Xu BH; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Sun Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
He J; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Feb 23; Vol. 43 (2), pp. 218-223.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
COVID-19*
Neoplasms*/drug therapy
China ; Clinical Trials as Topic ; Humans ; Medical Oncology ; SARS-CoV-2 ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Synthesis and Biological Evaluation of Oleanolic Acid Derivatives as Selective Vascular Endothelial Growth Factor Promoter i-Motif Ligands.
Autorzy:
Zeng H; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Kang S; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Zhang Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Liu K; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Yu Q; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Li D; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
An LK; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangzhou 510006, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 08; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 08.
Typ publikacji:
Evaluation Study; Journal Article
MeSH Terms:
Nucleotide Motifs*
Promoter Regions, Genetic*
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*drug therapy
Oleanolic Acid/*pharmacology
Vascular Endothelial Growth Factor A/*genetics
Antineoplastic Agents/chemistry ; Apoptosis ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Movement ; Cell Proliferation ; Female ; Humans ; Nucleic Acid Conformation ; Oleanolic Acid/chemistry ; Tumor Cells, Cultured ; Vascular Endothelial Growth Factor A/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Inhibition of ULK1 promotes the death of leukemia cell in an autophagy irrelevant manner and exerts the antileukemia effect.
Autorzy:
Yang W; The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.; Institute of Biomedical Engineering, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China.
Li Y; The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.
Liu S; The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.; Department of Laboratory, Shenzhen Sami International Medical Center (Shenzhen Fourth People's Hospital), Shenzhen, China.
Sun W; The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.
Huang H; The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Zhang Q; Institute of Biomedical Engineering, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China.
Yan J; The Second Affiliated Hospital, The State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2021 Jan; Vol. 11 (1), pp. e282.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Autophagy/*genetics
Autophagy-Related Protein-1 Homolog/*antagonists & inhibitors
Autophagy-Related Protein-1 Homolog/*genetics
Intracellular Signaling Peptides and Proteins/*antagonists & inhibitors
Intracellular Signaling Peptides and Proteins/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Animals ; Autophagy/drug effects ; Databases, Factual ; Disease Models, Animal ; Humans ; Leukemia, Myeloid, Acute/pathology ; Mice
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability.
Autorzy:
Sun B; Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
Jing H; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mabrouk MT; Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
Zhang Y; School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.
Jin H; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lovell JF; Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
Pokaż więcej
Źródło:
Pharmaceutical development and technology [Pharm Dev Technol] 2020 Dec; Vol. 25 (10), pp. 1281-1288. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Poloxamer/*chemistry
Surface-Active Agents/*chemistry
Taxoids/*administration & dosage
Animals ; Antineoplastic Agents/pharmacology ; Carcinoma, Lewis Lung/drug therapy ; Carcinoma, Lewis Lung/pathology ; Drug Stability ; Drug Storage ; Excipients/chemistry ; Humans ; Hydrophobic and Hydrophilic Interactions ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Mice ; Mice, Inbred C57BL ; Micelles ; Polysorbates/chemistry ; Taxoids/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Autorzy:
Layeghi-Ghalehsoukhteh S; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.; Department of Basic Science, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Pal Choudhuri S; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.
Ocal O; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.; Department of Molecular Biology and Genetics, Bilkent University, 06800, Ankara, Turkey.
Zolghadri Y; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.; Department of Basic Science, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Pashkov V; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.
Niederstrasser H; Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Posner BA; Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Kantheti HS; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.; Cancer Discovery (CanDisc) Group, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.
Azevedo-Pouly AC; Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Huang H; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Girard L; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA.; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
MacDonald RJ; Department of Molecular Biology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Brekken RA; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Wilkie TM; Department of Pharmacology, UT Southwestern Medical Center, 6001 Forest Park Drive, Dallas, TX, 75390, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Nov 26; Vol. 10 (1), pp. 20662. Date of Electronic Publication: 2020 Nov 26.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Adenocarcinoma/*pathology
Antineoplastic Agents/*pharmacology
Carcinoma, Pancreatic Ductal/*drug therapy
Carcinoma, Pancreatic Ductal/*pathology
Pancreatic Neoplasms/*drug therapy
Pancreatic Neoplasms/*pathology
Acinar Cells/drug effects ; Acinar Cells/metabolism ; Acinar Cells/pathology ; Adenocarcinoma/metabolism ; Animals ; Calcium/metabolism ; Carcinogenesis/drug effects ; Carcinogenesis/metabolism ; Carcinogenesis/pathology ; Carcinoma, Pancreatic Ductal/metabolism ; Cell Dedifferentiation/drug effects ; Cell Transformation, Neoplastic/drug effects ; Cell Transformation, Neoplastic/metabolism ; Cells, Cultured ; Ceruletide/metabolism ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Disease Progression ; GTP-Binding Proteins/metabolism ; Histone Deacetylase Inhibitors/pharmacology ; Mice ; Pancreatic Ducts/drug effects ; Pancreatic Ducts/metabolism ; Pancreatic Neoplasms/metabolism ; Pancreatitis/drug therapy ; Pancreatitis/metabolism ; Proto-Oncogene Proteins p21(ras)/metabolism ; RGS Proteins/metabolism ; Signal Transduction/drug effects ; Gemcitabine ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells.
Autorzy:
Huang Y; Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China.
Huang H; Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China.
Wang S; Department of Anesthesiology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China.
Chen F; Department of General Surgery, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China.
Zheng G; Department of General Surgery, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China.
Pokaż więcej
Źródło:
Molecular medicine reports [Mol Med Rep] 2020 Jul; Vol. 22 (1), pp. 43-50. Date of Electronic Publication: 2020 May 05.
Typ publikacji:
Journal Article
MeSH Terms:
Alkaloids/*pharmacology
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*drug therapy
Carcinogenesis/*drug effects
Alkaloids/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Breast Neoplasms/pathology ; Carcinogenesis/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Female ; Humans ; Mice ; Mice, SCID
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Autorzy:
Xu W; Department of Hematology, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Yang S; Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China.
Zhou K; Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Pan L; West China Hospital of Sichuan University, Chengdu, China.
Li Z; Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China.
Zhou J; Tongji Hospital, Tongji Medical College, Wuhan, China.
Gao S; The First Hospital of Jilin University, Changchun, China.
Zhou D; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hu J; Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Feng R; Nanfang Hospital of Southern Medical University, Guangzhou, China.
Huang H; The 1st Hospital of Soochow University, Suzhou, China.
Ji M; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene USA, Inc., San Mateo, CA, USA.
Guo H; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene USA, Inc., San Mateo, CA, USA.
Huang J; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene USA, Inc., San Mateo, CA, USA.
Novotny W; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene USA, Inc., San Mateo, CA, USA.
Feng S; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene USA, Inc., San Mateo, CA, USA.
Li J; Department of Hematology, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 May 11; Vol. 13 (1), pp. 48. Date of Electronic Publication: 2020 May 11.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Agammaglobulinaemia Tyrosine Kinase/*antagonists & inhibitors
Antineoplastic Agents/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; China/epidemiology ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/epidemiology ; Piperidines/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Autorzy:
Chen S; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China.
Hua L; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China.
Feng C; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China.
Mo Q; Department of Chemotherapy, Liuzhou Cancer Hospital, Liuzhou, 545006, Guangxi, China.
Wei M; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China.
Shen Y; Department of Oncology, The Liuzhou Railway Affiliated Hospital of Guangxi Medical University, Liuzhou, 545007, Guangxi, China.
Lin Z; Department of Oncology, The Yulin First People's Hospital, Yulin, 537000, Guangxi, China.
Li G; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China.
Xu J; Department of Gastroenterological Surgery, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, 545005, Guangxi, China. .
Guo C; Clinical Pharmacology Center, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China. .
Huang H; Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, No.1 liushi Road, Liuzhou, 545005, Guangxi, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2020 Apr 07; Vol. 20 (1), pp. 96. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji:
Journal Article
MeSH Terms:
Polymorphism, Genetic*
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*drug therapy
Glucuronosyltransferase/*genetics
Irinotecan/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Camptothecin/therapeutic use ; China ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/therapeutic use ; Follow-Up Studies ; Genotype ; Humans ; Irinotecan/adverse effects ; Kaplan-Meier Estimate ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Precision Medicine ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome
SCR Protocol:
IFL protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
X-ray tomography of cryopreserved human prostate cancer cells: mitochondrial targeting by an organoiridium photosensitiser.
Autorzy:
Bolitho EM; Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.; Diamond House, Harwell Science and Innovation Campus, Fermi Ave, Didcot, OX11 0DE, UK.
Sanchez-Cano C; Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, Donostia-San Sebastián, Spain. .
Huang H; Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.
Hands-Portman I; School of Life Sciences, University of Warwick, Gibbet Hill Campus, Coventry, CV4 7AL, UK.
Spink M; Diamond House, Harwell Science and Innovation Campus, Fermi Ave, Didcot, OX11 0DE, UK.
Quinn PD; Diamond House, Harwell Science and Innovation Campus, Fermi Ave, Didcot, OX11 0DE, UK.
Harkiolaki M; Diamond House, Harwell Science and Innovation Campus, Fermi Ave, Didcot, OX11 0DE, UK. .
Sadler PJ; Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. .
Pokaż więcej
Źródło:
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry [J Biol Inorg Chem] 2020 Mar; Vol. 25 (2), pp. 295-303. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cryopreservation*
Photochemotherapy*
Antineoplastic Agents/*pharmacology
Coordination Complexes/*pharmacology
Mitochondria/*drug effects
Photosensitizing Agents/*pharmacology
Prostatic Neoplasms/*drug therapy
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Coordination Complexes/chemical synthesis ; Coordination Complexes/chemistry ; Drug Screening Assays, Antitumor ; Humans ; Iridium/chemistry ; Iridium/pharmacology ; Male ; Mitochondria/metabolism ; Molecular Conformation ; PC-3 Cells ; Photosensitizing Agents/chemical synthesis ; Photosensitizing Agents/chemistry ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Tomography, X-Ray Computed
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comprehensive Effects of Near-Infrared Multifunctional Liposomes on Cancer Cells.
Autorzy:
Deng Y; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Huang H; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Chen M; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Chen G; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Zou W; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Zhao Y; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Zhao Q; School of Chemical Engineering, Sichuan University, No.24 South Section 1, Yihuan Road, Chengdu 610065, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2020 Mar 01; Vol. 25 (5). Date of Electronic Publication: 2020 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Hyperthermia, Induced*
Magnetic Fields*
Quantum Dots*/chemistry
Quantum Dots*/therapeutic use
Neoplasms/*therapy
Cell Survival ; Humans ; Infrared Rays ; Liposomes ; MCF-7 Cells ; Neoplasms/metabolism ; Neoplasms/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[Progress on clinical trials of cancer drugs in China, 2019].
Autorzy:
Huang HY; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wu DW; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang HX; National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Wang J; National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Fan Q; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang SH; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bai Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yu Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fang Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Sun C; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fang H; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Bai H; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100032, China.
Wang X; Beijing Institute of Geriatrics/Clinical Trial Center, Beijing Hospital, Beijing 100730, China.
Liu ZY; Clinical Pharmacology Research Center, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
Jiang M; National Drug Clinical Trials Institutions, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Liu Z; Oncology Medicine Department, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Wang XH; Phase Ⅰ Drug Clinical Trial Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Li HY; Cardiology Department & Drug Clinical Trial Institution, Peking University Third Hospital, Beijing 100191, China.
Li N; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Cao C; ZhongGuanCun JiuTai Good Clinical Practice Union, Beijing 100027, China.
Xu BH; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Sun Y; Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
He J; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Feb 23; Vol. 42 (2), pp. 127-132.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Lung Neoplasms/*drug therapy
China ; Clinical Trials as Topic ; Humans ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Antitumor, Antiviral, and Anti-Inflammatory Efficacy of Essential Oils from Atractylodes macrocephala Koidz. Produced with Different Processing Methods.
Autorzy:
Gu S; School of Pharmacy, Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, 1200 Cai-lun Rd, Shanghai 201203, China.
Li L; School of Pharmacy, Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, 1200 Cai-lun Rd, Shanghai 201203, China.
Huang H; Experimental Teaching Center of Pharmaceutical Sciences, School of Pharmacy, Fudan University, 826 Zhang-heng Rd, Shanghai 201203, China.
Wang B; School of Pharmacy, Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, 1200 Cai-lun Rd, Shanghai 201203, China. .; Center for Pharmaceutics Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China. .
Zhang T; School of Pharmacy, Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, 1200 Cai-lun Rd, Shanghai 201203, China. .
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2019 Aug 15; Vol. 24 (16). Date of Electronic Publication: 2019 Aug 15.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Inflammatory Agents/*pharmacology
Antineoplastic Agents/*pharmacology
Antiviral Agents/*pharmacology
Atractylodes/*chemistry
Oils, Volatile/*pharmacology
Plant Oils/*pharmacology
Anti-Inflammatory Agents/chemistry ; Antineoplastic Agents/chemistry ; Antiviral Agents/chemistry ; Chemical Fractionation ; Gas Chromatography-Mass Spectrometry ; Oils, Volatile/chemistry ; Oils, Volatile/isolation & purification ; Phytochemicals/chemistry ; Phytochemicals/pharmacology ; Plant Oils/chemistry ; Plant Oils/isolation & purification
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers.
Autorzy:
Leng X; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .
Dong X; Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. .
Wang W; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .
Sai N; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .; School of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China. .
Yang C; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .
You L; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. ylt_.
Huang H; National Center for International Joint Research on Membrane Science and Technology, Tianjin Polytechnic University, Tianjin 300387, China. .; State Key Laboratory of Separation Membranes and Membrane Processes, Tianjin Polytechnic University, Tianjin 300387, China. .
Yin X; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .; Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. .
Ni J; School of Chinese Material Medical, Beijing University of Chinese Medicine, Beijing 102488, China. .; Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. .
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2018 Sep 28; Vol. 23 (10). Date of Electronic Publication: 2018 Sep 28.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*chemistry
Diterpenes, Kaurane/*chemistry
Drug Carriers/*chemistry
Iron/*chemistry
Metal-Organic Frameworks/*chemistry
Antineoplastic Agents/administration & dosage ; Biocompatible Materials ; Cell Survival ; Cross-Linking Reagents/chemistry ; Diterpenes, Kaurane/administration & dosage ; Drug Liberation ; Hep G2 Cells ; Humans ; Hydrogen-Ion Concentration ; Kinetics ; Particle Size ; Phthalic Acids/chemistry ; Porosity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The anticancer effects of Cucurbitacin I inhibited cell growth of human non‑small cell lung cancer through PI3K/AKT/p70S6K pathway.
Autorzy:
Zhu X; Center of Oncology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Huang H; Center of Oncology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Zhang J; Department of Oncology, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610031, P.R. China.
Liu H; Center of Oncology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Ao R; Center of Oncology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Xiao M; Center of Oncology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Wu Y; Department of Gerontology, Chengdu First People's Hospital, Chengdu, Sichuan 610041, P.R. China.
Pokaż więcej
Źródło:
Molecular medicine reports [Mol Med Rep] 2018 Feb; Vol. 17 (2), pp. 2750-2756. Date of Electronic Publication: 2017 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Carcinoma, Non-Small-Cell Lung/*metabolism
Lung Neoplasms/*metabolism
Phosphatidylinositol 3-Kinases/*metabolism
Proto-Oncogene Proteins c-akt/*metabolism
Ribosomal Protein S6 Kinases, 70-kDa/*metabolism
Signal Transduction/*drug effects
Triterpenes/*pharmacology
Apoptosis/drug effects ; Caspase 3/metabolism ; Caspase 9/metabolism ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 58

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies